Bristol-Myers Squibb Company with ticker code (BMY) now have 22 analysts in total covering the stock. The consensus rating is pointing to ‘hold’. The range between the high target price and low target price is between $82.73 and $45.96 and has a mean target at $58.24. Given that the stocks previous close was at $51.57 and the analysts are correct then there would likely be a percentage uptick in value of 12.9%. There is a 50 day moving average of $55.79 and the 200 day MA is $63.57. The total market capitalization for the company now stands at 103.45B. The current share price for the company is: $50.84 USD
The potential market cap would be $116,826,923,327 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 12.9, revenue per share of $21.51 and a 5.59% return on assets.
Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It offers products for a range of therapeutic classes, which include oncology, immunology, cardiovascular and hematology. Its pharmaceutical products include chemically synthesized or small molecule drugs and products produced from biological processes, called biologics. Biologics are administered to patients through injections or by infusion. Its products include Revlimid, Abecma, Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Sprycel, Yervoy, Abraxane, Empliciti, Reblozyl, Inrebic, Onureg, Zeposia, Camzyos, and Breyanzi. It also has a pipeline of investigational medicines designed to target the common mutations associated with oncogenesis, including repotrectinib. Its products are sold to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies.
